Stifel Financial
COGT icon

Stifel Financial’s Cogent Biosciences COGT Stock Holding History

Stifel Financial’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$391K Buy
10,102
+762
+8% +$26.7K ﹤0.01% 3131
2026
Q1 		$359K Buy
+9,340
New +$345K ﹤0.01% 3064

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Stifel Financial's COGT Position: Q2 2026 in Review

Stifel Financial increased its Cogent Biosciences (COGT) stake by 8.2% in Q2 2026, buying an estimated $26.7K and bringing the position to 10,102 shares worth $391K. The position accounts for ﹤0.01% of the portfolio, ranked #3131.

Stifel Financial first reported a position in COGT in Q1 2026 and has held it in 2 quarters since. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Stifel Financial held 10,102 shares of Cogent Biosciences worth $391K as of Q2 2026.
  • Stifel Financial bought 762 Cogent Biosciences shares in Q2 2026, an estimated $26.7K.
  • Cogent Biosciences made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #3131 holding.
  • Stifel Financial first reported a position in Cogent Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.